Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing To Advance Next-Generation Precision Editing Therapeutics
PRIVATENov 09, 2021
Amount Raised
$215 Million
Round Type
Series B
Cambridge
Description
Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the completion of an oversubscribed and up-sized $215 million Series B financing. Including this round, the Company has raised over $300 million to date.
Who to call at Arbor, and when
A new round usually means Arbor is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Arbor raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Arbor, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Arbor. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Arbor
Location
Cambridge, Maryland, United States
About
We welcome Dr. Yu to the board and look forward to his contributions as the company works toward deploying these new therapies to treat patients in the near future.”
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Arbor raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Cambridge